Alejandro Neyra-Lopez

Nino Jesus, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Home-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial.

Home-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial.

Journal: The European respiratory journal

Published: November 07, 2025

Strength-Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial.

Strength-Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial.

Journal: Current protocols

Published: September 18, 2025

Consensus document for Severe Asthma. 2025 Update

Consensus document for Severe Asthma. 2025 Update

Journal: Open respiratory archives

Published: August 05, 2025

Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies.

Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies.

Journal: Children (Basel, Switzerland)

Published: June 04, 2025

Cardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study.

Cardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study.

Journal: ERJ open research

Published: February 07, 2025

Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives.

Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives.

Journal: Archivos de bronconeumologia

Published: October 08, 2024

Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics.

Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics.

Journal: ERJ open research

Published: July 15, 2024

Calcified Mediastinal Adenopathy: What If It Is Not Tuberculosis?

Calcified Mediastinal Adenopathy: What If It Is Not Tuberculosis?

Journal: Open respiratory archives

Published: July 27, 2023

SARS-CoV-2 infection in children with cystic fibrosis: A cross-sectional multicenter study in Spain. New waves, new knowledge.

SARS-CoV-2 infection in children with cystic fibrosis: A cross-sectional multicenter study in Spain. New waves, new knowledge.

Journal: Pediatric pulmonology

Published: April 05, 2023

Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease.

Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease.

Journal: Archivos de bronconeumologia

Published: March 22, 2023

Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.

Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

Published: February 27, 2023

Severe asthma resistant to biological treatment?

Severe asthma resistant to biological treatment?

Journal: Anales de pediatria

Published: July 26, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026